147807-80-5

Upstream product

• 75889-47-3 2,3-dimethoxy-4-methylbenzaldehyde 
• 25922-05-8 2-methyl-6-iodoanisole 
• 18102-30-2 2-methoxy-3-methylaniline 
• 18102-29-9 2-methyl-6-nitroanisole 
• 50-00-0 formaldehyd 
• 18102-31-3 2-methoxy-3-methylphenol 
• 13073-29-5 2-methyl-6-nitrophenol 
• 4463-33-6 1,2-dimethoxy-3-methylbenzene 

Downstream Products

• 123042-12-6 2-benzyloxy-3-methoxy-4-methylbenzaldehyde 
• 147807-88-3 N-(2,2-Diethoxyethyl)-N-<1-(2-benzyloxy-3-methoxy-4-methylphenyl)-2-benzyloxyethyl>toluene-p-sulfonamide 
• 147807-89-4 8-Benzyloxy-1-benzyloxymethyl-7-methoxy-6-methyl-2-(p-tolylsulfonyl)-1,2-dihydroisoquinoline 
• 147807-85-0 2-amino>acetaldehyde diethyl acetal 
• 147807-83-8 2-Benzyloxy-1-(2-benzyloxy-3-methoxy-4-methyl-phenyl)-ethanol 
• 147807-84-9 Benzyloxymethyl 2-benzyloxy-3-methoxy-4-methylphenyl ketone 
• 147807-81-6 (2-Benzyloxy-3-methoxy-4-methylphenyl)oxirane 

Relevant academic research and scientific papers

Total synthesis of the isoquinolinium metabolite ETM-204 of Trabectidin

Ecteinascidin-743 (Trabectidin, Trabectedin, Yondelis) is a synthetically obtained pharmaceutical drug originally isolated from a marine tunicate. Trabectedin is used for the chemotherapy of soft-tissue sarcoma and ovarian cancer. Th

Total synthesis of the β-adrenergic receptor antagonist, the tetrahydroisoquinoline MY336-a and its epimer

The first total synthesis of the novel β-adrenergic receptor antagonist MY336-a 1 and its epimer 2 has been achieved from 2,3-dimethoxytoluene, by Jackson cyclisation of N-benzyl-N-tosylamido acetals, Lewis acid-mediated addition of silicon-based nucleoph

Studies on the Natural β-Adrenergic Receptor Antagonist MY336-a: Synthesis of a 3-Dehydroxymethyl Analogue

The preparation of a polysubstituted tetrahydroisoquinoline, which lacks only the 3-CH2OH group of MY336-a, is described.